GSK Set to Acquire US Cancer Biotech IDRx in Landmark $1.15 Billion Deal
2 days ago
In a significant move within the pharmaceutical landscape, GlaxoSmithKline (GSK) has announced its intention to acquire U.S.-based cancer biotechnology firm IDRx for a staggering amount that could reach up to $1.15 billion. This bold acquisition underscores GSK's commitment to expanding its oncology portfolio as it aims to bolster its presence in the competitive cancer treatment market.
Continue reading
GSK Approaches $1 Billion Acquisition of Biotech Firm IDRX: A Strategic Move in the Pharma Landscape
7 days ago
GlaxoSmithKline (GSK) is reportedly in the final stages of negotiating a significant deal valued at around $1 billion to acquire the biotech company IDRX. This development signifies a substantial strategic maneuver within the pharmaceutical sector, as GSK aims to enhance its portfolio of drugs and expand its presence in the biotechnology landscape.
Continue reading